Renin-angiotensin-aldosterone system antagonists and the prevention of type 2 diabetes mellitus

Current Pharmaceutical Design

Volumn 18, Issue 7, 2012, Pages 958-962

  Stöhr, Robert ^a   Marx, Nikolaus ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

ACEi; ARB; Diabetes; Hypertension; RAS

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; APELIN RECEPTOR; ATENOLOL; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN RECEPTOR SUBSTRATE 1; LISINOPRIL; NATEGLINIDE; PERINDOPRIL; PLACEBO; RAMIPRIL; RESERPINE; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETOGENESIS; DRUG DOSE INCREASE; DRUG EFFICACY; FOLLOW UP; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BINDING; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 84857124526     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799436557     Document Type: Article

References (34)

1. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetescare 2005. 28(9): p. 2130-5.
2. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359(9323): p. 2072-7.
3. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes care 2005; 28(3): p. 736-44.
4. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-Gonzalez G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clinical endocrinology 2009; 71(1): p. 1-6.
5. Lastra G, Manrique C, McFarlane SI, Sowers JR. Cardiometabolic syndrome and chronic kidney disease. Current diabetes reports 2006; 6(3): p. 207-12.
6. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. The Journal of clinical investigation 1997; 100(9): p. 2158-69.
7. Wei Y, Sowers JR, Clark SE, et al. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. American journal of physiology. Endocrinology and metabolism 2008; 294(2): p. E345-51.
8. Sowers JR. Insulin resistance and hypertension. American journal of physiology, Heart and circulatory physiology 2004; 286(5): p. H1597-602.
9. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414(6865): p. 799-806.
10. Rett K, Wicklmayr M, Dietze GJ, Haring HU. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 1996; 45 Suppl1: p. S66-9.
11. Chappell MC, Millsted A, Diz DI, Brosnihan KB, Ferrario CM. Evidence for an intrinsic angiotensin system in the canine pancreas. Journal of hypertension 1991; 9(8): p. 751-9.
12. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue renin-angiotensin system in human pancreas. The Journal of endocrinology 1999; 161(2): p. 317-22.
13. Blendea MC, Jacobs D, Stump CS, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. American journal of physiology. Endocrinology and metabolism 2005; 288(2): p. E353-9.
14. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensinaldosterone system, glucose metabolism and diabetes. Trends in endocrinology and metabolism: TEM 2005; 16(3): p. 120-6.
15. Henriksen EJ, Jacob S, Kinnick TR, et al. ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide. The American journal of physiology 1999; 277(1 Pt 2): p. R332-6.
16. Kudoh A, Matsuki A. Effects of angiotensin-converting enzyme inhibitors on glucose uptake. Hypertension 2000; 36(2): p. 239-44.
17. Jacob S, Henriksen EJ, Fogt DL, Dietze GJ. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism: clinical and experimental 1996; 45(5): p. 535-41.
18. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353(9153): p. 611-6.
19. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. The New England journal of medicine 2000; 342(3): p. 145-53.
20. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA the journal of the American Medical Association 2001; 286(15): p. 1882-5.
21. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA the journal of the American Medical Association 2002; 288(23): p. 2981-97.
22. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): p. 782-8.
23. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensinconverting-enzyme inhibition in stable coronary artery disease. The New England journal of medicine 2004; 351(20): p. 2058-68.
24. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368(9535): p. 581-8.
25. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47(9): p. 1519-27.
26. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. The New England journal of medicine 2006; 355(15): p. 1551-62.
27. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. The New England journal of medicine 2010; 362(16): p. 1477-90.
28. MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature 1981; 291(5813): p. 329-31.
29. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society 2004-BHS IV. Journal of human hypertension 2004; 18(3): p. 139-85.
30. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. The New England journal of medicine 1993; 329(20): p. 1456-62.
31. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients ith nephropathy due to type 2 diabetes. The New England journal of medicine 2001; 345(12): p. 851-60.
32. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England journal of medicine 2001; 344(18): p. 1343-50.
33. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England journal of medicine 2002; 346(6): p. 393-403.
34. Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Samra AB. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Cardiology journal 2010; 17(5): p. 448-56.